US 2024/0391980 A1 · Anti-Human Astrovirus Antibodies and Related Compositions and Methods

Abstract

Provided are antibodies that specifically bind human astrovirus (HAstV) capsid spike protein. Fusion proteins and conjugates comprising such antibodies are also provided. Also provided are nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having or suspected of having a HAstV infection a therapeutically effective amount of an antibody, fusion protein or conjugate of the present disclosure.

An antibody that specifically binds to a human astrovirus (HAstV) capsid spike protein and competes for binding to the HAstV capsid spike protein with an antibody comprising:

a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFSLTSYGVH (SEQ ID NO:2),
a VH CDR2 comprising the amino acid sequence VIWSGGSTDYNAAFIS (SEQ ID NO:3), and
a VH CDR3 comprising the amino acid sequence NSLLDAMDY (SEQ ID NO:4), and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence KASQSVSNAVA (SEQ ID NO:6),
a VL CDR2 comprising the amino acid sequence YASNRYT (SEQ ID NO:7), and
a VL CDR3 comprising the amino acid sequence QQDYSSPLT (SEQ ID NO:8);
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GYTFTSYWMH (SEQ ID NO:10),
a VH CDR2 comprising the amino acid sequence EINPSSGRANYNEKFKN (SEQ ID NO:11), and
a VH CDR3 comprising the amino acid sequence DYYAMDY (SEQ ID NO:12), and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence RASQSISNNLH (SEQ ID NO:14),
a VL CDR2 comprising the amino acid sequence SASQSIS (SEQ ID NO:15), and
a VL CDR3 comprising the amino acid sequence QQTNSWPLT (SEQ ID NO:16);
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GYSITSGYYWN (SEQ ID NO:18),
a VH CDR2 comprising the amino acid sequence YISYDGSNNYNPSLKN (SEQ ID NO:19), and
a VH CDR3 comprising the amino acid sequence FYDGYDY (SEQ ID NO:20), and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence KASQDVSTAVA (SEQ ID NO:22),
a VL CDR2 comprising the amino acid sequence WASTRHT (SEQ ID NO:23), and
a VL CDR3 comprising the amino acid sequence QQHYSTPFT (SEQ ID NO:24);
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFSLTTFGIH (SEQ ID NO:26),
a VH CDR2 comprising the amino acid sequence VIWAAGTTNYNSTLKS (SEQ ID NO:27), and
a VH CDR3 comprising the amino acid sequence EDYDYFFGLDY (SEQ ID NO:28), and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence RSSTGAVTTSNYAS (SEQ ID NO:30),
a VL CDR2 comprising the amino acid sequence GTNNRAP (SEQ ID NO:31), and
a VL CDR3 comprising the amino acid sequence ALWFSNHWV (SEQ ID NO:32);
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFSLTSYGVH (SEQ ID NO:1),
a VH CDR2 comprising the amino acid sequence VIWADGSTNYNSALMS (SEQ ID NO:34), and
a VH CDR3 comprising the amino acid sequence WTYGDYFDY (SEQ ID NO:35), and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence SASQGISNYLN (SEQ ID NO:37),
a VL CDR2 comprising the amino acid sequence YTSSLHS (SEQ ID NO:38), and
a VL CDR3 comprising the amino acid sequence QQYSKLPYT (SEQ ID NO:39);
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFTFSYFGMH (SEQ ID NO:41),
a VH CDR2 comprising the amino acid sequence YISSGSNTIYYADTVKG (SEQ ID NO:42), and
a VH CDR3 comprising the amino acid sequence AYYGNHYYAMDF (SEQ ID NO:43), and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence RASENIYSNLA (SEQ ID NO:45),
a VL CDR2 comprising the amino acid sequence AARDLAT (SEQ ID NO:46), and
a VL CDR3 comprising the amino acid sequence QHFWETPWT (SEQ ID NO:47);
or
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFTFSDYYMY (SEQ ID NO:49),
a VH CDR2 comprising the amino acid sequence TISDGGFSTYYPDSVKG (SEQ ID NO:50), and
a VH CDR3 comprising the amino acid sequence FGAYSTF (SEQ ID NO:51), and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence RASSSVSYMY (SEQ ID NO:53),
a VL CDR2 comprising the amino acid sequence ATSNLAS (SEQ ID NO:54), and
a VL CDR3 comprising the amino acid sequence QQWSSDPPMT (SEQ ID NO:55).

54 more elements

Anti-Human Astrovirus Antibodies and Related Compositions and Methods

Life of this patent

Anti-Human Astrovirus Antibodies and Related Compositions and Methods

Life of this patent

Abstract

Claims46